18:00 , Sep 28, 2018 |  BC Week In Review  |  Company News

Novartis to cut Swiss, U.K. jobs to adapt manufacturing

Novartis AG (NYSE:NVS; SIX:NOVN) revealed restructuring plans that could remove a net of up to 1,700 Swiss-based jobs over four years as the pharma continues to evolve its business services organization and manufacturing strategy, spokesperson...
16:42 , Jul 20, 2018 |  BC Week In Review  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced on July 18 that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its...
19:59 , Jul 18, 2018 |  BC Extra  |  Company News

Novartis halts price increases, reports 2Q earnings

Novartis AG (NYSE:NVS; SIX:NOVN) announced Wednesday that it will suspend for the rest of the year price increases in the U.S. The pharma made the announcement in conjunction with the release of its 2Q18 earnings....
18:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7...
20:52 , Jun 29, 2018 |  BC Extra  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7...
00:37 , Jan 26, 2018 |  BC Extra  |  Politics & Policy

Narasimhan dines with Trump in Davos

Soon-to-be CEO of Novartis AG (NYSE:NVS; SIX:NOVN) Vasant Narasimhan attended a dinner with President Trump at the World Economic Forum in Davos, Switzerland on Thursday. The pharma declined to comment on what was discussed at...
00:26 , Jan 25, 2018 |  BC Extra  |  Company News

Novartis gains ex-U.S. rights to Spark's gene therapy, and reports earnings

Novartis AG (NYSE:NVS; SIX:NOVN) gained ex-U.S. rights to develop and commercialize voretigene neparvovec-rzyl from Spark Therapeutics Inc. (NASDAQ:ONCE). The pharma also reported its 4Q17 earnings on Wednesday. Spark will receive $105 million up front and...
21:38 , Jan 5, 2018 |  BC Week In Review  |  Financial News

Oculis raises CHF20M series B

Oculis S.A. (Lausanne, Switzerland) raised CHF20 million ($20.3 million) on Jan. 4 in a tranched series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners with participation by existing investors...
08:02 , Jan 4, 2018 |  BC Extra  |  Financial News

Oculis raises CHF20M series B

Oculis ehf (Lausanne, Switzerland) raised CHF20 million ($20.3 million) in a series B round led by Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors Brunnur Ventures and Silfurberg also participated. The...
23:56 , Nov 3, 2017 |  BioCentury  |  Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....